- Home
- FISI vs MYGN Comparison
FISI vs MYGN Comparison
Compare FISI & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FISI
- MYGN
- Stock Information
- Founded
- FISI 1817
- MYGN 1991
- Country
- FISI United States
- MYGN United States
- Employees
- FISI N/A
- MYGN N/A
- Industry
- FISI Major Banks
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- FISI Finance
- MYGN Health Care
- Exchange
- FISI Nasdaq
- MYGN Nasdaq
- Market Cap
- FISI 500.2M
- MYGN 423.1M
- IPO Year
- FISI 1999
- MYGN 1995
- Fundamental
- Price
- FISI $25.78
- MYGN $5.71
- Analyst Decision
- FISI Buy
- MYGN Hold
- Analyst Count
- FISI 3
- MYGN 15
- Target Price
- FISI $33.00
- MYGN $15.14
- AVG Volume (30 Days)
- FISI 133.9K
- MYGN 2.4M
- Earning Date
- FISI 07-24-2025
- MYGN 08-05-2025
- Dividend Yield
- FISI 4.77%
- MYGN N/A
- EPS Growth
- FISI N/A
- MYGN N/A
- EPS
- FISI N/A
- MYGN N/A
- Revenue
- FISI $102,639,000.00
- MYGN $832,900,000.00
- Revenue This Year
- FISI $122.14
- MYGN N/A
- Revenue Next Year
- FISI $4.97
- MYGN $6.64
- P/E Ratio
- FISI N/A
- MYGN N/A
- Revenue Growth
- FISI N/A
- MYGN 3.83
- 52 Week Low
- FISI $20.97
- MYGN $3.76
- 52 Week High
- FISI $29.79
- MYGN $29.30
- Technical
- Relative Strength Index (RSI)
- FISI 48.83
- MYGN 58.57
- Support Level
- FISI $24.62
- MYGN $3.76
- Resistance Level
- FISI $26.72
- MYGN $6.52
- Average True Range (ATR)
- FISI 0.78
- MYGN 0.35
- MACD
- FISI 0.09
- MYGN 0.16
- Stochastic Oscillator
- FISI 55.24
- MYGN 70.65
About FISI Financial Institutions Inc.
Financial Institutions Inc operates as a financial holding company, engages in the provision of a wide range of consumer and commercial banking services to individuals, municipalities, and businesses in Western and Central New York. It operates through one segment: The Banking segment which includes all of the company's retail and commercial banking operations.
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.